Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes with Nonexudative AMD Trial (PREVENT): A Prospective Controlled
Maziar Lalezary, MD
Updates from the Field
2018
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020
High-Dose Anti-VEGF: Cross-Trial Analysis of Different Doses and Antagonists for the Treatment of Diabetic Macular Edema
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more